NUVB

+ Watchlist + Portfolio

Nuvation Bio Inc. Class A

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.26
52-Week Range: $2.76 – $9.75
Market Cap: $2.40B
P/E (TTM): —
EPS (TTM): -0.41
Dividend Yield: —

Advanced Metrics

Price/Book: 9.41
PEG Ratio: —
Return on Equity: -47.81%
Return on Assets: -12.36%
Gross Margin: 88.18%
Operating Margin: -161.06%
Profit Margin: -88.19%
Current Ratio: 8.37
Debt/Equity: 1.64
Total Debt: $416.26M
Free Cash Flow: $-112.11M
Revenue Growth: 555.60%
Earnings Growth: —
Enterprise Value: $2.15B

NUVB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$7.87M	$62.90M
Cost of Revenue	—	$0.00	$7.08M	$9.30M
Gross Profit	—	$0.00	$795.00K	$53.60M
Research & Development	$87.81M	$71.29M	$99.12M	$115.11M
Selling, General & Admin	$31.92M	$28.53M	$69.23M	$151.56M
Operating Expenses	$119.73M	$99.82M	$168.35M	$266.67M
Operating Income	-$119.73M	-$99.82M	-$167.56M	-$213.06M
EBITDA	-$119.53M	-$75.58M	-$566.91M	-$189.21M
Pretax Income	-$104.20M	-$75.80M	-$567.94M	-$204.63M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$104.20M	-$75.80M	-$567.94M	-$204.63M
Diluted EPS	-0.48	-0.35	-2.11	-0.60
Diluted Shares	216.72M	218.88M	268.77M	341.54M

NUVB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$101.10M	$42.65M	$35.72M	$164.09M
Receivables	$2.48M	$3.70M	$16.29M	$19.36M
Inventory	—	—	$0.00	$11.41M
Current Assets	$667.32M	$616.43M	$526.25M	$571.52M
Total Assets	$672.14M	$621.48M	$540.63M	$594.82M
Current Liabilities	$13.16M	$13.97M	$58.24M	$82.23M
Long-Term Debt	—	—	—	$47.21M
Total Debt	$4.26M	$4.01M	$8.91M	$57.35M
Total Liabilities	$17.07M	$16.36M	$76.84M	$289.11M
Retained Earnings	-$267.00M	-$342.80M	-$910.74M	-$1.12B
Shareholders' Equity	$655.08M	$605.12M	$463.79M	$305.72M
Working Capital	$654.16M	$602.46M	$468.01M	$489.29M

NUVB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$96.11M	-$68.00M	-$130.41M	-$173.43M
Capital Expenditure	-$370.00K	-$69.00K	-$162.00K	-$8.35M
Free Cash Flow	-$96.48M	-$68.07M	-$130.57M	-$181.78M
Depreciation & Amortisation	$199.00K	$222.00K	$683.00K	$1.74M
Stock-Based Compensation	$16.29M	$19.51M	$32.27M	$35.89M
Investing Cash Flow	$63.46M	$8.92M	$122.70M	$99.52M
Financing Cash Flow	$1.33M	$628.00K	$331.00K	$202.53M
Net Change in Cash	-$31.32M	-$58.45M	-$7.38M	$128.63M

NUVB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$3.08M	$4.83M	$13.12M	$41.87M	$83.23M
Cost of Revenue	$2.09M	$2.58M	$3.35M	$1.28M	$5.99M
Gross Profit	$990.00K	$2.26M	$9.77M	$40.59M	$77.24M
Research & Development	$24.60M	$27.36M	$28.85M	$34.30M	$35.05M
Selling, General & Admin	$35.39M	$38.48M	$37.36M	$40.33M	$38.31M
Operating Expenses	$59.99M	$65.85M	$66.20M	$74.62M	$73.36M
Operating Income	-$59.00M	-$63.59M	-$56.43M	-$34.04M	$3.88M
EBITDA	-$52.87M	-$58.23M	-$48.72M	-$29.38M	$12.64M
Pretax Income	-$53.24M	-$59.01M	-$55.79M	-$36.59M	$5.40M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$53.24M	-$59.01M	-$55.79M	-$36.59M	$5.40M
Diluted EPS	-0.16	-0.17	-0.16	-0.11	0.01
Diluted Shares	338.61M	340.75M	342.39M	344.34M	377.52M

NUVB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$47.98M	$247.97M	$98.90M	$164.09M	$125.39M
Receivables	$5.46M	$6.68M	$13.85M	$19.36M	$25.98M
Inventory	$14.00K	$552.00K	$5.71M	$11.41M	$15.84M
Current Assets	$475.57M	$623.21M	$577.53M	$571.52M	$591.53M
Total Assets	$492.49M	$647.23M	$601.56M	$594.82M	$610.24M
Current Liabilities	$52.77M	$66.36M	$68.13M	$82.23M	$79.52M
Long-Term Debt	—	$46.97M	$47.09M	$47.21M	$47.33M
Total Debt	$11.41M	$57.76M	$57.55M	$57.35M	$57.15M
Total Liabilities	$73.03M	$274.32M	$275.68M	$289.11M	$290.68M
Retained Earnings	-$963.98M	-$1.02B	-$1.08B	-$1.12B	-$1.11B
Shareholders' Equity	$419.46M	$372.91M	$325.88M	$305.72M	$319.56M
Working Capital	$422.80M	$556.85M	$509.40M	$489.29M	$512.01M

NUVB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$42.63M	-$48.18M	-$52.89M	-$29.73M	$5.07M
Capital Expenditure	-$72.00K	-$181.00K	-$8.01M	-$89.00K	-$48.00K
Free Cash Flow	-$42.70M	-$48.36M	-$60.90M	-$29.82M	$5.02M
Depreciation & Amortisation	$310.00K	$356.00K	$534.00K	$539.00K	$536.00K
Stock-Based Compensation	$7.85M	$12.03M	$8.02M	$7.99M	$9.03M
Investing Cash Flow	$54.18M	$54.88M	-$96.62M	$87.08M	-$43.64M
Financing Cash Flow	$548.00K	$193.42M	$501.00K	$8.06M	$44.00K
Net Change in Cash	$12.10M	$200.12M	-$149.01M	$65.41M	-$38.52M

Market Snapshot

About

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company developing precision oncology therapies. The company focuses on cancer treatments targeting specific genetic alterations and tumor biology mechanisms.